ATE339197T1 - 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten - Google Patents

4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten

Info

Publication number
ATE339197T1
ATE339197T1 AT03727265T AT03727265T ATE339197T1 AT E339197 T1 ATE339197 T1 AT E339197T1 AT 03727265 T AT03727265 T AT 03727265T AT 03727265 T AT03727265 T AT 03727265T AT E339197 T1 ATE339197 T1 AT E339197T1
Authority
AT
Austria
Prior art keywords
methyl
treatment
benzamide
ylmethyl
pyrimidine
Prior art date
Application number
AT03727265T
Other languages
English (en)
Inventor
Richard Ernest Gilbert
Darren James Kelly
David Louis Feldman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0206216A external-priority patent/GB0206216D0/en
Priority claimed from GB0206217A external-priority patent/GB0206217D0/en
Priority claimed from GB0217505A external-priority patent/GB0217505D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE339197T1 publication Critical patent/ATE339197T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03727265T 2002-03-15 2003-03-14 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten ATE339197T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0206216A GB0206216D0 (en) 2002-03-15 2002-03-15 Organic compounds
GB0206217A GB0206217D0 (en) 2002-03-15 2002-03-15 Organic compounds
GB0217505A GB0217505D0 (en) 2002-07-29 2002-07-29 Organic compounds

Publications (1)

Publication Number Publication Date
ATE339197T1 true ATE339197T1 (de) 2006-10-15

Family

ID=28045959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03727265T ATE339197T1 (de) 2002-03-15 2003-03-14 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten

Country Status (11)

Country Link
US (1) US20050124624A1 (de)
EP (1) EP1487424B1 (de)
JP (1) JP2005527523A (de)
AT (1) ATE339197T1 (de)
AU (1) AU2003233946A1 (de)
CY (1) CY1105839T1 (de)
DE (1) DE60308337T2 (de)
DK (1) DK1487424T3 (de)
ES (1) ES2274234T3 (de)
PT (1) PT1487424E (de)
WO (1) WO2003077892A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037261A1 (en) * 2002-10-25 2004-05-06 The Administrators Of The Tulane Educational Fund Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
US20050171172A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
BRPI0507030A (pt) * 2004-01-22 2007-06-05 Novartis Ag combinação de compostos orgánicos
GB0401761D0 (en) * 2004-01-27 2004-03-03 Novartis Ag Organic compounds
MY144177A (en) * 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
EP1741432A1 (de) * 2005-07-07 2007-01-10 Universitätsklinikum Freiburg Tyrosinkinase-Inhibitor Imatinib zur Behandlung von Bluthochdruck
DE102005042544A1 (de) * 2005-09-07 2007-03-08 Ernst-Moritz-Arndt-Universität Beeinflussung des kardialen Fc-Rezeptors zur Behandlung der dilatativen Kardiomyopathie
WO2007084949A2 (en) * 2006-01-18 2007-07-26 The Uab Research Foundation Modulators of cardiac cell hypertrophy and hyperplasia
MX2008011843A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Polimorfos de n-(4-cloro-3-metil-5-isoxazolil)2-[2-metil-4,5-(meti lendioxi)fenilacetil]tiofeno-3-sulfonamida, sal de sodio.
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
TW201006823A (en) * 2008-07-14 2010-02-16 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
EP4054579A1 (de) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur behandlung von krebsarten, die resistenz gegen kinase-inhibitoren erworben haben
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US20010051631A1 (en) * 1994-07-15 2001-12-13 Muneo Takatani Tricyclic compounds, their production and use
PL185150B1 (pl) * 1995-06-07 2003-03-31 Searle & Co Kompozycja farmaceutyczna do leczenia zaburzeń sercowo-naczyniowych
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso

Also Published As

Publication number Publication date
JP2005527523A (ja) 2005-09-15
EP1487424B1 (de) 2006-09-13
ES2274234T3 (es) 2007-05-16
DE60308337D1 (de) 2006-10-26
WO2003077892A3 (en) 2003-12-24
US20050124624A1 (en) 2005-06-09
EP1487424A2 (de) 2004-12-22
AU2003233946A8 (en) 2003-09-29
DK1487424T3 (da) 2007-01-08
DE60308337T2 (de) 2007-09-20
WO2003077892A2 (en) 2003-09-25
PT1487424E (pt) 2007-01-31
CY1105839T1 (el) 2011-04-06
AU2003233946A1 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
CY1105839T1 (el) 4-(4-μεθυλπιπepαζιν-1-υλμεθυλ)-ν-[4-μεθυλ-3-(4-πυριδιν-3-υλ)πυριμιδιν-2-υλ-αμινο)φαινυλ]-βενζαμιδη για τη θepαπεια αng ii - μεσολαβουμενων ασθενειων
NO20076323L (no) Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metyl-fenyl}-4-(3-pyridyl)-2-pyrimidinamin og en aromataseinhibitor, anvendelse av kombinasjonen samt farmasøytisk preparat
CY1105055T1 (el) Θepαπεια γαστρεντepικων στρωματικων ογκων
NO20044093L (no) N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin belagte stenter
IL164678A (en) High-drug tablet containing 4– (4-methylpiprazine – 1-ylamethyl) -n - [(4-methyl-3– (4-pyridin-3-il) pyrimidine-2-ylamino) phenyl] -benzamide or compatible salt Its pharmaceutical and process for its preparation
AR053984A1 (es) Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas
ATE521354T1 (de) Kombination aus imatinib und einem histondeacetylase-hemmer zur behandlung von leukämie
IL176070A0 (en) COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF
BR0207649A (pt) Combinação compreendendo um inibidor de transdução de sinal e um derivado de epotilona
ATE468855T1 (de) Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
HK1087638A1 (en) Use of tyrosine kinase inhibitors to treat diabetes
ATE476183T1 (de) Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
SI1487424T1 (sl) 4-(4-metilpiperazin-1-ilmetil)-N-(4-metil-3(4-piridin-3-il)pirimidin-2- il-amino)fenil)-benzamid za zdravljenje bolezni, posredovanih preko ang II

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1487424

Country of ref document: EP